{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T20:27:47Z","timestamp":1787862467405,"version":"build-2784847793"},"reference-count":53,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T00:00:00Z","timestamp":1775606400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100018694","name":"European Commission Marie Sklodowska-Curie Actions","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018694","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005378","name":"Hacettepe University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005378","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.ejps.2026.107527","type":"journal-article","created":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T17:33:20Z","timestamp":1775756000000},"page":"107527","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["CD44-targeted cyclodextrin-hyaluronic acid nanoparticles carrying gemcitabine and paclitaxel to pancreatic cancer"],"prefix":"10.1016","volume":"221","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1291-9503","authenticated-orcid":false,"given":"Gamze","family":"Varan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nurbanu","family":"Demirt\u00fcrk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sibel","family":"G\u00f6k\u015fen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan M.","family":"Benito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milo","family":"Malanga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00fcleyman Can","family":"\u00d6zt\u00fcrk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00fcne\u015f","family":"Esenda\u011fl\u0131","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erem","family":"Bilensoy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejps.2026.107527_bib0001","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.933457","article-title":"Recent nanotechnology advancements to treat multidrug-resistance pancreatic cancer: pre-clinical and clinical overview","volume":"13","author":"Alshememry","year":"2022","journal-title":"Front. Pharmacol."},{"issue":"12","key":"10.1016\/j.ejps.2026.107527_bib0002","article-title":"Pancreatic cancer chemoresistance to gemcitabine","volume":"9","author":"Amrutkar","year":"2017","journal-title":"Cancers. (Basel)"},{"key":"10.1016\/j.ejps.2026.107527_bib0003","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2025.125869","article-title":"Gemcitabine-loaded ICOS-fc decorated nanosponges: a new chemo immunotherapy combination against pancreatic cancer","volume":"682","author":"Argenziano","year":"2025","journal-title":"Int. J. Pharm."},{"issue":"3 Pt A","key":"10.1016\/j.ejps.2026.107527_bib0004","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.ejpb.2013.06.003","article-title":"Hyaluronic acid-coated liposomes for active targeting of gemcitabine","volume":"85","author":"Arpicco","year":"2013","journal-title":"Eur. J. Pharm. Biopharm."},{"issue":"Suppl 3","key":"10.1016\/j.ejps.2026.107527_bib0005","first-page":"S58","article-title":"Pancreatic ductal adenocarcinoma epidemiology and risk assessment: could we prevent? Possibility for an early diagnosis","volume":"6","author":"Bekkali","year":"2017","journal-title":"Endosc. Ultrasound."},{"key":"10.1016\/j.ejps.2026.107527_bib0006","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2025.107958","article-title":"Hyaluronic acid and its role in pancreatic cancer: mechanisms of tumor progression, drug resistance, and therapeutic targeting","volume":"221","author":"Cai","year":"2025","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.ejps.2026.107527_bib0007","doi-asserted-by":"crossref","DOI":"10.1038\/s41419-022-05103-1","article-title":"Gemcitabine resistance of pancreatic cancer cells is mediated by IGF1R dependent upregulation of CD44 expression and isoform switching","volume":"13","author":"Chen","year":"2022","journal-title":"Cell Death Dis."},{"issue":"5","key":"10.1016\/j.ejps.2026.107527_bib0008","first-page":"1396","article-title":"Targeting gemcitabine containing liposomes to CD44 expressing pancreatic adenocarcinoma cells causes an increase in the antitumoral activity","volume":"1828","author":"Dalla Pozza","year":"2013","journal-title":"Biochim. Biophys. Acta (BBA)\u2014Mol. Cell Biol. Lipids"},{"issue":"1","key":"10.1016\/j.ejps.2026.107527_bib0009","first-page":"1","article-title":"Analytical methods of six FDA approved molecular entities used for the treatment of non-small cell lung cancer: a concise review","volume":"8","author":"Das","year":"2018","journal-title":"Int. J. Pharm."},{"issue":"2","key":"10.1016\/j.ejps.2026.107527_bib0010","article-title":"Cholesterol metabolism in pancreatic cancer and associated therapeutic strategies","volume":"1870","author":"Daya","year":"2025","journal-title":"Biochim. Biophys. Acta (BBA)\u2014Mol. Cell Biol. Lipids"},{"key":"10.1016\/j.ejps.2026.107527_bib0011","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.ejpb.2021.11.006","article-title":"Nanocarriers targeting the diseases of the pancreas","volume":"170","author":"Demirt\u00fcrk","year":"2022","journal-title":"Eur. J. Pharm. Biopharm."},{"issue":"2","key":"10.1016\/j.ejps.2026.107527_bib0012","first-page":"269","article-title":"Pharmacokinetics of gemcitabine and correlation with response and toxicity in patients with advanced pancreatic cancer","volume":"68","author":"Di Paolo","year":"2011","journal-title":"Cancer Chemother. Pharmacol"},{"key":"10.1016\/j.ejps.2026.107527_bib0013","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1039\/b718672j","article-title":"Rational design of cationic cyclooligosaccharides as efficient gene delivery systems","volume":"17","author":"D\u00edaz-Moscoso","year":"2008","journal-title":"Chem. Commun. (Camb)"},{"key":"10.1016\/j.ejps.2026.107527_bib0014","first-page":"360","article-title":"Tunable hybrid hydrogels with multicellular spheroids for modeling desmoplastic pancreatic cancer","volume":"25","author":"Ermis","year":"2023","journal-title":"Bioact. Mater."},{"issue":"6","key":"10.1016\/j.ejps.2026.107527_bib0015","article-title":"The role of the tumor microenvironment in pancreatic ductal adenocarcinoma: recent advancements and emerging therapeutic strategies","volume":"17","author":"Glapi\u0144ski","year":"2025","journal-title":"Cancers. (Basel)"},{"key":"10.1016\/j.ejps.2026.107527_bib0016","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1287459","article-title":"Pancreatic cancer tumor microenvironment is a major therapeutic barrier and target","volume":"15","author":"Hartupee","year":"2024","journal-title":"Front. Immunol."},{"issue":"15","key":"10.1016\/j.ejps.2026.107527_bib0017","article-title":"Cyclodextrins and derivatives in drug delivery: new developments, relevant clinical trials, and advanced products","volume":"324","author":"Kali","year":"2024","journal-title":"Carbohydr. Polym."},{"key":"10.1016\/j.ejps.2026.107527_bib0018","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.800481","article-title":"CD44-Targeted nanocarrier for cancer therapy","volume":"12","author":"Kesharwani","year":"2022","journal-title":"Front. Pharmacol."},{"issue":"8","key":"10.1016\/j.ejps.2026.107527_bib0019","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22083953","article-title":"Targeting the stromal pro-tumoral hyaluronan-CD44 pathway in pancreatic cancer","volume":"22","author":"Koltai","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejps.2026.107527_bib0020","doi-asserted-by":"crossref","DOI":"10.1186\/s12967-024-05528-6","article-title":"Insights into gemcitabine resistance in pancreatic cancer: association with metabolic reprogramming and TP53 pathogenicity in patient derived xenografts","volume":"22","author":"Konat\u00e9","year":"2024","journal-title":"J. Transl. Med."},{"issue":"43","key":"10.1016\/j.ejps.2026.107527_bib0021","doi-asserted-by":"crossref","first-page":"36628","DOI":"10.1021\/acsami.8b08243","article-title":"Tumor targeting and lipid rafts disrupting hyaluronic acid-cyclodextrin-based nanoassembled structure for cancer therapy","volume":"10","author":"Lee","year":"2018","journal-title":"ACS. Appl. Mater. Interfaces."},{"issue":"1","key":"10.1016\/j.ejps.2026.107527_bib0022","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.2147\/DDDT.S447496","article-title":"Advances in nanotechnology for enhancing the solubility and bioavailability of poorly soluble drugs","volume":"18","author":"Liu","year":"2024","journal-title":"Drug. Devel. Ther."},{"issue":"1","key":"10.1016\/j.ejps.2026.107527_bib0023","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1023\/A:1022263111961","article-title":"Direct formation of nanospheres from amphiphilic beta-cyclodextrin inclusion complexes","volume":"20","author":"Memi\u015fo\u011flu","year":"2003","journal-title":"Pharm. Res."},{"issue":"4","key":"10.1016\/j.ejps.2026.107527_bib0024","doi-asserted-by":"crossref","first-page":"3540","DOI":"10.1021\/acsnano.5b00510","article-title":"Use of a lipid-coated mesoporous silica nanoparticle platform for synergistic gemcitabine and paclitaxel delivery to Human pancreatic cancer in mice","volume":"9","author":"Meng","year":"2015","journal-title":"ACS. Nano"},{"issue":"12","key":"10.1016\/j.ejps.2026.107527_bib0025","doi-asserted-by":"crossref","DOI":"10.3390\/cancers16122240","article-title":"Pancreatic ductal adenocarcinoma (PDAC): a review of recent advancements enabled by artificial intelligence","volume":"16","author":"Mukund","year":"2024","journal-title":"Cancers. (Basel)"},{"issue":"3","key":"10.1016\/j.ejps.2026.107527_bib0026","doi-asserted-by":"crossref","first-page":"288","DOI":"10.3390\/pharmaceutics17030288","article-title":"Cyclodextrins: enhancing drug delivery, solubility and bioavailability for Modern therapeutics","volume":"17","author":"Nicolaescu","year":"2025","journal-title":"Pharmaceutics."},{"key":"10.1016\/j.ejps.2026.107527_bib0027","article-title":"Development and In vitro and In vivo efficacy investigation of multifunctional, targeted, theranostic liposomes for imaging and photodynamic therapy of glioblastoma","volume":"101","author":"Onaral","year":"2024","journal-title":"J. Drug Deliv. Sci. Technol."},{"issue":"2","key":"10.1016\/j.ejps.2026.107527_bib0028","doi-asserted-by":"crossref","first-page":"186","DOI":"10.3390\/vaccines13020186","article-title":"Development and characterization of an In vitro cell-based assay to predict potency of mRNA-LNP-based vaccines","volume":"13","author":"Patel","year":"2025","journal-title":"Vaccines. (Basel)"},{"issue":"8","key":"10.1016\/j.ejps.2026.107527_bib0029","doi-asserted-by":"crossref","first-page":"4241","DOI":"10.3390\/curroncol31080316","article-title":"Focus on pancreatic cancer microenvironment","volume":"31","author":"Prattic\u00f2","year":"2024","journal-title":"Curr. Oncol."},{"issue":"4","key":"10.1016\/j.ejps.2026.107527_bib0030","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1038\/bjc.2016.215","article-title":"Superior therapeutic efficacy of nab-paclitaxel over cremophor-based paclitaxel in locally advanced and metastatic models of human pancreatic cancer","volume":"115","author":"Rajeshkumar","year":"2016","journal-title":"Br. J. Cancer"},{"issue":"1","key":"10.1016\/j.ejps.2026.107527_bib0031","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1038\/s41467-020-15889-3","article-title":"Size and surface charge characterization of nanoparticles with a salt gradient","volume":"11","author":"Rasmussen","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejps.2026.107527_bib0032","doi-asserted-by":"crossref","DOI":"10.1016\/j.carbpol.2024.122776","article-title":"\u03b2-cyclodextrin-based geometrically frustrated amphiphiles as one-component, cell-specific and organ-specific nucleic acid delivery systems","volume":"347","author":"Rivero-Barbarroja","year":"2025","journal-title":"Carbohydr. Polym."},{"issue":"5","key":"10.1016\/j.ejps.2026.107527_bib0033","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1111\/cas.12913","article-title":"Role of hyaluronan in pancreatic cancer biology and therapy: once again in the spotlight","volume":"107","author":"Sato","year":"2016","journal-title":"Cancer Sci."},{"issue":"4","key":"10.1016\/j.ejps.2026.107527_bib0034","doi-asserted-by":"crossref","first-page":"4959","DOI":"10.1002\/jcp.27297","article-title":"Combination therapy for the treatment of pancreatic cancer through hyaluronic acid-decorated nanoparticles loaded with quercetin and gemcitabine: a preliminary in vitro study","volume":"234","author":"Serri","year":"2019","journal-title":"J. Cell. Physiol"},{"key":"10.1016\/j.ejps.2026.107527_bib0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2024.122788","article-title":"Survivin (BIRC5): implications in cancer therapy","volume":"350","author":"Siragusa","year":"2024","journal-title":"Life Sci."},{"key":"10.1016\/j.ejps.2026.107527_bib0036","doi-asserted-by":"crossref","first-page":"921","DOI":"10.2147\/IJN.S185458","article-title":"Apoptosis-promoting effect of rituximab-conjugated magnetic nanoprobes on malignant lymphoma cells with CD20 overexpression","volume":"14","author":"Song","year":"2019","journal-title":"Int. J. Nanomed."},{"issue":"6","key":"10.1016\/j.ejps.2026.107527_bib0037","doi-asserted-by":"crossref","first-page":"2481","DOI":"10.1021\/acs.molpharmaceut.9b00083","article-title":"Evaluating the efficiency of hyaluronic acid for tumor targeting via CD44","volume":"16","author":"Spadea","year":"2019","journal-title":"Mol. Pharm"},{"issue":"5","key":"10.1016\/j.ejps.2026.107527_bib0038","doi-asserted-by":"crossref","DOI":"10.3390\/molecules23051228","article-title":"Cyclodextrins: assessing the impact of cavity size, occupancy, and substitutions on cytotoxicity and cholesterol homeostasis","volume":"23","author":"Szente","year":"2018","journal-title":"Molecules."},{"key":"10.1016\/j.ejps.2026.107527_bib0039","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.jconrel.2019.05.018","article-title":"Can intracellular drug delivery using hyaluronic acid functionalised pH-sensitive liposomes overcome gemcitabine resistance in pancreatic cancer?","volume":"305","author":"Tang","year":"2019","journal-title":"J. Control. Release"},{"issue":"3","key":"10.1016\/j.ejps.2026.107527_bib0040","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1097\/00006676-200310000-00004","article-title":"Establishment of gemcitabine-resistant Human pancreatic cancer cells and effect of Brefeldin-A on the resistant","volume":"27","author":"Togawa","year":"2003","journal-title":"Pancreas."},{"key":"10.1016\/j.ejps.2026.107527_bib0041","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.3762\/bjnano.8.145","article-title":"Development of polycationic amphiphilic cyclodextrin nanoparticles for anticancer drug delivery","volume":"8","author":"Varan","year":"2017","journal-title":"Beilstein. J. Nanotechnol."},{"issue":"2","key":"10.1016\/j.ejps.2026.107527_bib0042","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.ijpharm.2017.06.010","article-title":"Amphiphilic cyclodextrin nanoparticles","volume":"531","author":"Varan","year":"2017","journal-title":"Int. J. Pharm."},{"issue":"10","key":"10.1016\/j.ejps.2026.107527_bib0043","doi-asserted-by":"crossref","first-page":"3172","DOI":"10.1016\/j.xphs.2016.06.021","article-title":"Cholesterol-targeted anticancer and apoptotic effects of anionic and polycationic amphiphilic cyclodextrin nanoparticles","volume":"105","author":"Varan","year":"2016","journal-title":"J. Pharm. Sci."},{"issue":"2","key":"10.1016\/j.ejps.2026.107527_bib0044","doi-asserted-by":"crossref","DOI":"10.3390\/nano11020515","article-title":"Therapeutic efficacy and biodistribution of paclitaxel-bound amphiphilic cyclodextrin nanoparticles: analyses in 3D tumor culture and tumor-bearing animals In vivo","volume":"11","author":"Varan","year":"2021","journal-title":"Nanomaterials"},{"key":"10.1016\/j.ejps.2026.107527_bib0045","doi-asserted-by":"crossref","DOI":"10.1186\/s12951-024-02975-7","article-title":"Novel insight and perspectives of nanoparticle-mediated gene delivery and immune-modulating therapies for pancreatic cancer","volume":"22","author":"Wang","year":"2024","journal-title":"J. Nanobiotechnology."},{"issue":"9","key":"10.1016\/j.ejps.2026.107527_bib0046","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.3748\/wjg.v23.i9.1594","article-title":"miR-1181 inhibits invasion and proliferation via STAT3 in pancreatic cancer","volume":"23","author":"Wang","year":"2017","journal-title":"World J. Gastroenterol"},{"key":"10.1016\/j.ejps.2026.107527_bib0047","doi-asserted-by":"crossref","DOI":"10.1038\/natrevmats.2016.14","article-title":"Analysis of nanoparticle delivery to tumours","volume":"1","author":"Wilhelm","year":"2016","journal-title":"Nat. Rev. Mater."},{"key":"10.1016\/j.ejps.2026.107527_bib0048","article-title":"Heterogeneity of chemosensitivity in pancreatic cancer: preclinical evaluation of gemcitabine-resistant cell lines","volume":"6","author":"Wong","year":"2016","journal-title":"Sci. Rep."},{"issue":"2","key":"10.1016\/j.ejps.2026.107527_bib0049","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/nrgastro.2014.1","article-title":"Pancreatic tumour formation and recurrence after radiotherapy are blocked by targeting CD44","volume":"11","author":"Wood","year":"2014","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"issue":"24 Pt B","key":"10.1016\/j.ejps.2026.107527_bib0050","doi-asserted-by":"crossref","first-page":"4097","DOI":"10.1016\/j.febslet.2015.11.009","article-title":"Targeting cholesterol with \u03b2-cyclodextrin sensitizes cancer cells for apoptosis","volume":"589","author":"Yamaguchi","year":"2015","journal-title":"FEBS Lett."},{"issue":"4","key":"10.1016\/j.ejps.2026.107527_bib0051","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1021\/acsptsci.3c00304","article-title":"Polydopamine-based resveratrol-hyaluronidase nanomedicine inhibited pancreatic cancer cell invasive phenotype in hyaluronic acid enrichment tumor sphere model","volume":"7","author":"Yu","year":"2024","journal-title":"ACS Pharmacol. Transl. Sci."},{"issue":"3","key":"10.1016\/j.ejps.2026.107527_bib0052","first-page":"3065","article-title":"Establishment and characterization of the gemcitab-resistant human pancreatic cancer cell line SW1990\/gemcitabine","volume":"18","author":"Yu","year":"2019","journal-title":"Oncol. Lett."},{"issue":"2","key":"10.1016\/j.ejps.2026.107527_bib0053","first-page":"394","article-title":"Co-delivery of gemcitabine and paclitaxel using a hyaluronic acid-based nanoparticle for pancreatic cancer therapy","volume":"6","author":"Zhang","year":"2018","journal-title":"Biomater. Sci."}],"container-title":["European Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098726001016?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098726001016?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T11:52:01Z","timestamp":1779709921000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0928098726001016"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":53,"alternative-id":["S0928098726001016"],"URL":"https:\/\/doi.org\/10.1016\/j.ejps.2026.107527","relation":{},"ISSN":["0928-0987"],"issn-type":[{"value":"0928-0987","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"CD44-targeted cyclodextrin-hyaluronic acid nanoparticles carrying gemcitabine and paclitaxel to pancreatic cancer","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejps.2026.107527","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"107527"}}